廣告
香港股市 將收市，收市時間：5 小時 49 分鐘

  • 恒指

    18,401.24
    +194.11 (+1.07%)
     

  • 國指

    6,519.94
    +82.85 (+1.29%)
     

  • 上證綜指

    3,104.82
    -8.22 (-0.26%)
     

  • 滬深300

    3,604.39
    -19.52 (-0.54%)
     

  • 美元

    7.8115
    -0.0018 (-0.02%)
     

  • 人民幣

    0.9263
    +0.0002 (+0.02%)
     

  • 道指

    38,225.66
    +322.37 (+0.85%)
     

  • 標普 500

    5,064.20
    +45.81 (+0.91%)
     

  • 納指

    15,840.96
    +235.48 (+1.51%)
     

  • 日圓

    0.0509
    +0.0003 (+0.57%)
     

  • 歐元

    8.3858
    +0.0080 (+0.10%)
     

  • 英鎊

    9.8050
    +0.0130 (+0.13%)
     

  • 紐約期油

    79.14
    +0.19 (+0.24%)
     

  • 金價

    2,310.40
    +0.80 (+0.03%)
     

  • Bitcoin

    59,707.39
    +2,354.12 (+4.10%)
     

  • CMC Crypto 200

    1,279.32
    +8.57 (+0.68%)
     

Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics

Zacks Equity Research
·2 分鐘文章

For the quarter ended December 2023, Heron Therapeutics (HRTX) reported revenue of $34.23 million, up 14% over the same period last year. EPS came in at -$0.07, compared to -$0.17 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $30.98 million, representing a surprise of +10.52%. The company delivered an EPS surprise of +53.33%, with the consensus EPS estimate being -$0.15.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

廣告

Here is how Heron Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Product sales- Sustol: $3.80 million versus the two-analyst average estimate of $3.44 million. The reported number represents a year-over-year change of +26.6%.

  • Product sales- Aponvie: $0.47 million versus $0.44 million estimated by two analysts on average.

  • Product sales- Zynrelef: $5.69 million compared to the $4.45 million average estimate based on two analysts. The reported number represents a change of +46% year over year.

  • Product sales- Cinvanti: $24.27 million versus $22.65 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.

View all Key Company Metrics for Heron Therapeutics here>>>

Shares of Heron Therapeutics have returned -8.4% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Heron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research